DACLIZUMAB Side Effects

6992590-X | Blood Creatinine Increased, Cytomegalovirus Viraemia, Diarrhoea, Hypogammaglobulinaemia, Pancytopenia, Pneumonia, Sepsis
on Sep 13, 2010 Male patient from TURKEY , 43 years of age, was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: blood creatinine increased, cytomegalovirus viraemia, diarrhoea, hypogammaglobulinaemia, pancytopenia, pneumonia (What is pneumonia?), sepsis (What is sepsis?). Daclizumab dosage: For Induction. During the same period patient was treated with RITUXIMAB (For 4 Weeks; Form Infusion) (View Rituximab Review and Rituximab Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.

6980305-0 | Cerebral Disorder, Fungal Infection, Lung Infiltration, Mucormycosis, Paresis Cranial Nerve, Zygomycosis
Patient was taking Daclizumab (View Usage). Patient had the following side effects: cerebral disorder, fungal infection (What is fungal infection?), lung infiltration, mucormycosis, paresis cranial nerve, zygomycosis on Sep 01, 2010 from GERMANY Additional patient health information: Male patient , 45 years of age, was diagnosed with graft versus host disease, thrombotic microangiopathy and. Daclizumab dosage: . During the same period patient was treated with CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHYLPREDNISOLONE (View Methylprednisolone Review and Methylprednisolone Label ), ANTI THYMOCYTE GLOBULIN NOS (View Anti-thymocyte Globulin Nos Review and Anti-thymocyte Globulin Nos Label ), PENTOSTATIN (View Pentostatin Review and Pentostatin Label ). Patient was hospitalized.

6636345-4 | Neutropenia, Nocardiosis
Adverse event was reported on Mar 01, 2010 by a Male patient taking Daclizumab (View Usage) (Dosage: ) was diagnosed with acute graft versus host disease, prophylaxis against graft versus host disease, antifungal prophylaxis and. Location: FRANCE , 55 years of age, After Daclizumab was administered, patient had the following side effects: neutropenia, nocardiosis. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), SULFAMETHOXAZOLE AND TRIMETHOPRIM (View Sulfamethoxazole And Trimethoprim Review and Sulfamethoxazole And Trimethoprim Label ), VALGANCICLOVIR HCL (View Valganciclovir Hcl Review and Valganciclovir Hcl Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), POSACONAZOLE (View Posaconazole Review and Posaconazole Label ), PENICILLIN V (2 Millions Unit Daily) (View Penicillin V Review and Penicillin V Label ), PENTAMIDINE ISETHIONATE (View Pentamidine Isethionate Review and Pentamidine Isethionate Label ).

6590363-3 | Cytomegalovirus Viraemia, Diarrhoea, Graft Dysfunction, Hyperkalaemia, Transplant Rejection
on Feb 03, 2010 Male patient from UNITED STATES , weighting 84.22 lb, was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cytomegalovirus viraemia, diarrhoea, graft dysfunction, hyperkalaemia, transplant rejection. Daclizumab dosage: . During the same period patient was treated with ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), COREG (View Coreg Review and Coreg Label ), RENAGEL (View Renagel Review and Renagel Label ), PHOSLO (View Phoslo Review and Phoslo Label ), PROTONIX (View Protonix Review and Protonix Label ), DULCOLAX (View Dulcolax Review and Dulcolax Label ), NIFEDIPINE (Procardia) (View Nifedipine Review and Nifedipine Label ). Patient was hospitalized.


6504955-0 | Cytomegalovirus Infection
on Dec 14, 2009 Male patient from IRELAND , 46 years of age, was diagnosed with cytomegalovirus infection (What is cytomegalovirus infection?) and was treated with Daclizumab (View Usage). Patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?). Daclizumab dosage: . During the same period patient was treated with VALGANCICLOVIR HCL (View Valganciclovir Hcl Review and Valganciclovir Hcl Label ), MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.

6450704-4 | Bacterial Sepsis, Chronic Myeloid Leukaemia, Hepatic Cirrhosis
Patient was taking Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: bacterial sepsis, chronic myeloid leukaemia, hepatic cirrhosis on Nov 16, 2009 from UNITED STATES Additional patient health information: Male patient , 45 years of age, was diagnosed with graft versus host disease and. Daclizumab dosage: . During the same period patient was treated with PREDNISONE (View Prednisone Review and Prednisone Label ), SIROLIMUS (View Sirolimus Review and Sirolimus Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), IMATINIB (View Imatinib Review and Imatinib Label ).

6442896-8 | Eczema, Macular Oedema
Adverse event was reported on Nov 09, 2009 by a Female patient taking Daclizumab (View Usage) (Dosage: Administered At Baseline; Form: Infusion) . Location: UNITED STATES , child 10 years of age, Patient experienced the following unwanted or unexpected effects: eczema (What is eczema?), macular oedema. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), AZATHIOPRINE (View Azathioprine Review and Azathioprine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ), PRED FORTE (Three Times A Day In Right Eye For Six Days And Two Times A Day In Left Eye For Three Days) (View Pred Forte Review and Pred Forte Label ).

6441067-9 | Herpes Zoster, Palpitations
on Nov 09, 2009 Female patient from UNITED STATES , 17 years of age, was treated with Daclizumab (View Usage). Patient had the following side effects: herpes zoster, palpitations. Daclizumab dosage: Administered At Baseline; Form Infusion.

6413278-X | Graft Dysfunction, Hyperkalaemia, Transplant Rejection
on Oct 14, 2009 Male patient from UNITED STATES , weighting 97.66 lb, was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: graft dysfunction, hyperkalaemia, transplant rejection. Daclizumab dosage: . During the same period patient was treated with ENALAPRIL MALEATE (View Enalapril Maleate Review and Enalapril Maleate Label ), COREG (View Coreg Review and Coreg Label ), RENAGEL (View Renagel Review and Renagel Label ), PHOSLO (View Phoslo Review and Phoslo Label ), PROTONIX (View Protonix Review and Protonix Label ), DULCOLAX (View Dulcolax Review and Dulcolax Label ), NIFEDIPINE (Procardia) (View Nifedipine Review and Nifedipine Label ). Patient was hospitalized.

6382000-8 | Cytomegalovirus Infection, Graft Versus Host Disease, Sepsis
Patient was taking Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cytomegalovirus infection (What is cytomegalovirus infection?), graft versus host disease, sepsis (What is sepsis?) on Sep 18, 2009 from GERMANY Additional patient health information: Male patient , 33 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Daclizumab dosage: On Day 1 And 2. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6381971-3 | Graft Versus Host Disease, Sepsis
Adverse event was reported on Sep 18, 2009 by a Male patient taking Daclizumab (View Usage) (Dosage: On Day 1 And 2) was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Location: GERMANY , 54 years of age, Patient had the following side effects: graft versus host disease, sepsis (What is sepsis?). During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6381966-X | Cerebral Toxoplasmosis, Cytomegalovirus Infection, Graft Versus Host Disease
on Sep 18, 2009 Male patient from GERMANY , 32 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: cerebral toxoplasmosis, cytomegalovirus infection (What is cytomegalovirus infection?), graft versus host disease. Daclizumab dosage: On Day 1-5. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380716-0 |
on Sep 18, 2009 Male patient from GERMANY , 52 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and was treated with Daclizumab (View Usage). . Daclizumab dosage: On Day 1 And 2. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380715-9 | Cytomegalovirus Infection, Sepsis
Patient was taking Daclizumab (View Usage). Patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), sepsis (What is sepsis?) on Sep 18, 2009 from GERMANY Additional patient health information: Female patient , 45 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Daclizumab dosage: On Day 1-5. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), METHYLPREDNISOLONE 4MG TAB (View Methylprednisolone 4mg Tab Review and Methylprednisolone 4mg Tab Label ).

6380714-7 | Cytomegalovirus Infection, Graft Versus Host Disease, Sepsis
Adverse event was reported on Sep 18, 2009 by a Male patient taking Daclizumab (View Usage) (Dosage: On Day 1 And 2) was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Location: GERMANY , 52 years of age, After Daclizumab was administered, patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), graft versus host disease, sepsis (What is sepsis?). During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380708-1 | Graft Versus Host Disease, Sepsis
on Sep 18, 2009 Female patient from GERMANY , 28 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: graft versus host disease, sepsis (What is sepsis?). Daclizumab dosage: On Day 1 And 2. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380315-0 | Cytomegalovirus Infection, Graft Versus Host Disease, Sepsis
on Sep 18, 2009 Male patient from GERMANY , 47 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and was treated with Daclizumab (View Usage). Patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), graft versus host disease, sepsis (What is sepsis?). Daclizumab dosage: On Day 1 And 2. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380314-9 | Leukaemia Recurrent, Sepsis
Patient was taking Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: leukaemia recurrent, sepsis (What is sepsis?) on Sep 18, 2009 from GERMANY Additional patient health information: Female patient , 56 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Daclizumab dosage: On Day 1-5. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380309-5 | Cytomegalovirus Infection
Adverse event was reported on Sep 18, 2009 by a Male patient taking Daclizumab (View Usage) (Dosage: On Day 1-5) was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Location: GERMANY , 23 years of age, Patient experienced the following unwanted or unexpected effects: cytomegalovirus infection (What is cytomegalovirus infection?). During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380308-3 | Aspergillosis, Cytomegalovirus Infection, Sepsis
on Sep 18, 2009 Male patient from GERMANY , 21 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and was treated with Daclizumab (View Usage). Patient had the following side effects: aspergillosis, cytomegalovirus infection (What is cytomegalovirus infection?), sepsis (What is sepsis?). Daclizumab dosage: On Day 1-5. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380307-1 | Leukaemia Recurrent, Sepsis
on Sep 18, 2009 Female patient from GERMANY , 61 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: leukaemia recurrent, sepsis (What is sepsis?). Daclizumab dosage: On Day 1 And 2. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380302-2 | Cytomegalovirus Infection, Herpes Simplex, Sepsis
Patient was taking Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: cytomegalovirus infection (What is cytomegalovirus infection?), herpes simplex (What is herpes simplex?), sepsis (What is sepsis?) on Sep 18, 2009 from GERMANY Additional patient health information: Male patient , 55 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Daclizumab dosage: On Day 1-5. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380301-0 | Acute Respiratory Distress Syndrome, Graft Versus Host Disease, Sepsis
Adverse event was reported on Sep 18, 2009 by a Male patient taking Daclizumab (View Usage) (Dosage: On Day 1 And 2) was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and. Location: GERMANY , 44 years of age, Patient had the following side effects: acute respiratory distress syndrome, graft versus host disease, sepsis (What is sepsis?). During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (According Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6380300-9 | Cytomegalovirus Infection, Graft Versus Host Disease, Sepsis
on Sep 18, 2009 Female patient from GERMANY , 34 years of age, was diagnosed with graft versus host disease, prophylaxis against graft versus host disease and was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: cytomegalovirus infection (What is cytomegalovirus infection?), graft versus host disease, sepsis (What is sepsis?). Daclizumab dosage: On Day 1-5. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CSA (Acorrding Plasma Levels) (View Csa Review and Csa Label ), PREDNISOLONE (On Day 7-13) (View Prednisolone Review and Prednisolone Label ).

6348837-6 | Glomerulonephritis Membranoproliferative
on Aug 28, 2009 Female patient from UNITED STATES , weighting 46.96 lb, was diagnosed with renal transplant and was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: glomerulonephritis membranoproliferative. Daclizumab dosage: . During the same period patient was treated with DULCOLAX (View Dulcolax Review and Dulcolax Label ), NIFEDIPINE (View Nifedipine Review and Nifedipine Label ), TYLENOL W/ CODEINE (View Tylenol W/ Codeine Review and Tylenol W/ Codeine Label ), AMPICILLIN (View Ampicillin Review and Ampicillin Label ). Patient was hospitalized.

6343649-1 | Transplant Rejection
Patient was taking Daclizumab (View Usage). Patient had the following side effects: transplant rejection on Aug 27, 2009 from UNITED STATES Additional patient health information: Female patient , weighting 141.1 lb, was diagnosed with renal transplant and. Daclizumab dosage: Form: Infusion, Frequency: Qow. During the same period patient was treated with FAMOTIDINE (View Famotidine Review and Famotidine Label ), HYDROCORTISONE CREAM (View Hydrocortisone Cream Review and Hydrocortisone Cream Label ), PROGRAF (View Prograf Review and Prograf Label ), CELLCEPT (View Cellcept Review and Cellcept Label ). Patient was hospitalized.

6256945-3 | Mycobacterium Kansasii Infection, Pseudomonas Infection, Sepsis, Strongyloidiasis
Adverse event was reported on Jun 09, 2009 by a Male patient taking Daclizumab (View Usage) (Dosage: ) . Location: UNITED STATES , 61 years of age, After Daclizumab was administered, patient had the following side effects: mycobacterium kansasii infection, pseudomonas infection, sepsis (What is sepsis?), strongyloidiasis. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), PROGRAF (View Prograf Review and Prograf Label ), CORTICOSTEROID NOS (View Corticosteroid Nos Review and Corticosteroid Nos Label ).

6241748-6 | Acid Fast Bacilli Infection, Haemoglobin Decreased, Pneumonia
on Oct 21, 2003 Male patient from UNITED KINGDOM , weighting 203.3 lb, was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: acid fast bacilli infection, haemoglobin decreased, pneumonia (What is pneumonia?). Daclizumab dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), SIROLIMUS (View Sirolimus Review and Sirolimus Label ). Patient was hospitalized.

6241652-3 | Bacterial Infection, Sepsis
on Nov 29, 2005 Female patient from AUSTRIA , weighting 101.4 lb, was treated with Daclizumab (View Usage). Patient had the following side effects: bacterial infection (What is bacterial infection?), sepsis (What is sepsis?). Daclizumab dosage: First Dose 24 Hours Pre-transplant (as Per Protocol). During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241642-0 | Hepatic Cyst Infection, Renal Cyst Infection, Sepsis
Patient was taking Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: hepatic cyst infection, renal cyst infection, sepsis (What is sepsis?) on Nov 22, 2004 from CZECH REPUBLIC Additional patient health information: Male patient , weighting 194.0 lb, . Daclizumab dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241637-7 | Complications Of Transplanted Kidney, Urinary Tract Infection
Adverse event was reported on Sep 20, 2005 by a Male patient taking Daclizumab (View Usage) (Dosage: A One Off Dose Of 2mg/kg Given 24 Hours Pre-transplant.) . Location: SPAIN , weighting 220.5 lb, Patient experienced the following unwanted or unexpected effects: complications of transplanted kidney, urinary tract infection (What is urinary tract infection?). During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6241635-3 | Culture Urine Positive, Escherichia Infection, Immunosuppression, Klebsiella Infection, Pseudomonas Infection, Pyelonephritis, Pyelonephritis Acute, Urinary Tract Infection
on Nov 29, 2004 Female patient from CANADA , weighting 124.8 lb, was treated with Daclizumab (View Usage). Patient had the following side effects: culture urine positive, escherichia infection, immunosuppression, klebsiella infection, pseudomonas infection, pyelonephritis, pyelonephritis acute, urinary tract infection (What is urinary tract infection?). Daclizumab dosage: Baseline Visit. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241632-8 | Bronchopneumonia
on Oct 08, 2004 Female patient from CZECH REPUBLIC , weighting 133.4 lb, was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: bronchopneumonia. Daclizumab dosage: Dose: As Per Protocol.. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6241628-6 | Pneumonia
Patient was taking Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia (What is pneumonia?) on Jan 13, 2005 from CZECH REPUBLIC Additional patient health information: Male patient , weighting 100.3 lb, . Daclizumab dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), SIROLIMUS (View Sirolimus Review and Sirolimus Label ). Patient was hospitalized.

6241625-0 | Diarrhoea, Graft Loss
Adverse event was reported on Dec 02, 2004 by a Male patient taking Daclizumab (View Usage) (Dosage: ) . Location: BRAZIL , weighting 99.21 lb, Patient had the following side effects: diarrhoea, graft loss. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), SIROLIMUS (View Sirolimus Review and Sirolimus Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized and became disabled.

6241624-9 | Cytomegalovirus Enteritis
on Dec 20, 2004 Male patient from SPAIN , weighting 148.4 lb, was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: cytomegalovirus enteritis. Daclizumab dosage: Baseline Visit.. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241622-5 | Gastrointestinal Haemorrhage, Sepsis
on May 09, 2005 Male patient from CZECH REPUBLIC , weighting 169.8 lb, was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: gastrointestinal haemorrhage, sepsis (What is sepsis?). Daclizumab dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), PREDNISONE (View Prednisone Review and Prednisone Label ). Patient was hospitalized.

6241620-1 | Blood Creatinine Increased, Urethral Fistula, Urinary Tract Infection
Patient was taking Daclizumab (View Usage). Patient had the following side effects: blood creatinine increased, urethral fistula, urinary tract infection (What is urinary tract infection?) on Jul 18, 2004 from CZECH REPUBLIC Additional patient health information: Male patient , weighting 133.4 lb, . Daclizumab dosage: Baseline Visit. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241619-5 | Cytomegalovirus Viraemia
Adverse event was reported on Jul 23, 2004 by a Male patient taking Daclizumab (View Usage) (Dosage: ) . Location: TURKEY , weighting 154.3 lb, After Daclizumab was administered, patient had the following side effects: cytomegalovirus viraemia. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241618-3 | Upper Respiratory Tract Infection
on May 30, 2005 Male patient from SPAIN , weighting 119.0 lb, was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: upper respiratory tract infection. Daclizumab dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6241615-8 | Pancreatitis Acute
on Sep 23, 2004 Male patient from CZECH REPUBLIC , weighting 198.4 lb, was treated with Daclizumab (View Usage). Patient had the following side effects: pancreatitis acute. Daclizumab dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), SIROLIMUS (View Sirolimus Review and Sirolimus Label ). Patient was hospitalized.

6241613-4 | Herpes Zoster
Patient was taking Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: herpes zoster on Nov 14, 2004 from SPAIN Additional patient health information: Male patient , weighting 185.2 lb, . Daclizumab dosage: Baseline Visit. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.

6241612-2 | Pyelonephritis Acute, Renal Cell Carcinoma
Adverse event was reported on Apr 25, 2005 by a Male patient taking Daclizumab (View Usage) (Dosage: ) . Location: GERMANY , weighting 157.6 lb, Patient experienced the following unwanted or unexpected effects: pyelonephritis acute, renal cell carcinoma. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), SIROLIMUS (View Sirolimus Review and Sirolimus Label ). Patient was hospitalized.

6241610-9 | Leiomyosarcoma
on Jan 09, 2007 Male patient from GERMANY , weighting 194.0 lb, was treated with Daclizumab (View Usage). Patient had the following side effects: leiomyosarcoma. Daclizumab dosage: Baseline Visit. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ). Patient was hospitalized.

6241609-2 | Benign Prostatic Hyperplasia, Blood Creatinine Increased, Epididymitis, Hyperglycaemia, Orchitis, Sepsis, Urinary Retention, Urinary Tract Infection, Urosepsis
on Jan 04, 2006 Male patient from ISRAEL , weighting 158.7 lb, was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: benign prostatic hyperplasia, blood creatinine increased, epididymitis, hyperglycaemia, orchitis, sepsis (What is sepsis?), urinary retention, urinary tract infection (What is urinary tract infection?), urosepsis. Daclizumab dosage: Loading Dose. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ). Patient was hospitalized.

6241608-0 | Influenza Like Illness
Patient was taking Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: influenza like illness on Jun 22, 2006 from AUSTRIA Additional patient health information: Male patient , weighting 165.3 lb, . Daclizumab dosage: Baseline Visit. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241607-9 | Anaemia, Blood Creatinine Increased, Cytomegalovirus Infection, Thrombocytopenia
Adverse event was reported on Jan 02, 2004 by a Male patient taking Daclizumab (View Usage) (Dosage: A One Off Dose Of 2mg/kg Given 24 Hours Pre-transplant.) . Location: TURKEY , weighting 154.3 lb, Patient had the following side effects: anaemia, blood creatinine increased, cytomegalovirus infection (What is cytomegalovirus infection?), thrombocytopenia. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), DILTIAZEM (View Diltiazem Review and Diltiazem Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ). Patient was hospitalized.

6241604-3 | Hydronephrosis, Leukopenia, Lymphocele, Ureteric Stenosis
on Jan 10, 2005 Male patient from CANADA , weighting 187.4 lb, was treated with Daclizumab (View Usage). After Daclizumab was administered, patient had the following side effects: hydronephrosis, leukopenia, lymphocele, ureteric stenosis. Daclizumab dosage: Formulation As Per Protocol. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ). Patient was hospitalized.

6241603-1 | Pneumonia Fungal, Retroperitoneal Haematoma, Sepsis, Subcutaneous Abscess
on Feb 17, 2005 Male patient from GERMANY , weighting 176.4 lb, was treated with Daclizumab (View Usage). Patient experienced the following unwanted or unexpected effects: pneumonia fungal, retroperitoneal haematoma, sepsis (What is sepsis?), subcutaneous abscess. Daclizumab dosage: . During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), TACROLIMUS (View Tacrolimus Review and Tacrolimus Label ), URBASON (View Urbason Review and Urbason Label ), VALCYTE (View Valcyte Review and Valcyte Label ). Patient was hospitalized.

6241598-0 | Arthritis Bacterial, Pyrexia, Urinary Tract Infection
Patient was taking Daclizumab (View Usage). Patient had the following side effects: arthritis bacterial, pyrexia, urinary tract infection (What is urinary tract infection?) on Oct 21, 2005 from GERMANY Additional patient health information: Male patient , weighting 183.0 lb, . Daclizumab dosage: Baseline Visit. During the same period patient was treated with MYCOPHENOLATE MOFETIL (View Mycophenolate Mofetil Review and Mycophenolate Mofetil Label ), PREDNISOLONE (View Prednisolone Review and Prednisolone Label ). Patient was hospitalized.